- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01706796
A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State
23 de enero de 2013 actualizado por: Pfizer
A Phase 1, Open Label, Randomized, Single Dose, 5 Period Crossover Relative Bioavailability Study In Healthy Volunteers Evaluating Spray Dried Dispersion (SDD) Immediate Release (IR) PF-06273340 Tablet, Two SDD Modified Release (MR) Matrix Tablets In Comparison With PF-06273340 Oral Solution, Including Preliminary Assessment Of Food Effect
The primary purpose of this study is to estimate the relative bioavailability and food effect of PF-06273340 tablets.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
12
Fase
- Fase 1
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Singapore, Singapur, 188770
- Pfizer Investigational Site
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
21 años a 55 años (Adulto)
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Healthy male and/or female subjects of non-child bearing potential, between the ages of 21 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
- An informed consent document signed and dated by the subject.
- Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- A positive urine drug screen.
- History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
- Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.
- Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
- Screening supine blood pressure >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), on a single measurement (confirmed by a single repeat, if necessary) following at least 5 minutes of rest.
- Evidence or history of orthostatic hypotension.
- 12-lead ECG demonstrating QTc >450 or a QRS interval >120 msec at Screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility.
- Pregnant or nursing females; females of childbearing potential, including those with tubal ligation.
- Use of prescription or nonprescription drugs, vitamins and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal supplements must be discontinued 28 days prior to the first dose of study medication. As an exception, acetaminophen/paracetamol may be used at doses of <=1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- Subjects who are investigational site staff members or relatives of those site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: PF-06273340 Oral Solution Fasted
|
Oral solution, single dose, fasted
Immediate Release Tablet, single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fasted
Modified Release Tablet (long duration, MR2), single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fed
Modified Release Tablet (long duration, MR2), single dose, fed
|
Experimental: PF-06273340 Immediate Release Tablet Fasted
|
Oral solution, single dose, fasted
Immediate Release Tablet, single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fasted
Modified Release Tablet (long duration, MR2), single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fed
Modified Release Tablet (long duration, MR2), single dose, fed
|
Experimental: PF-06273340 Modified Release (MR1) Tablet Fasted
|
Oral solution, single dose, fasted
Immediate Release Tablet, single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fasted
Modified Release Tablet (long duration, MR2), single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fed
Modified Release Tablet (long duration, MR2), single dose, fed
|
Experimental: PF-06273340 Modified Release (MR2) Tablet Fasted
|
Oral solution, single dose, fasted
Immediate Release Tablet, single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fasted
Modified Release Tablet (long duration, MR2), single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fed
Modified Release Tablet (long duration, MR2), single dose, fed
|
Experimental: PF-06273340 Modified Release (MR1) Tablet Fed
|
Oral solution, single dose, fasted
Immediate Release Tablet, single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fasted
Modified Release Tablet (long duration, MR2), single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fed
Modified Release Tablet (long duration, MR2), single dose, fed
|
Experimental: PF-06273340 Modified Release (MR2) Tablet Fed
|
Oral solution, single dose, fasted
Immediate Release Tablet, single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fasted
Modified Release Tablet (long duration, MR2), single dose, fasted
Modified Release Tablet (short duration, MR1), single dose, fed
Modified Release Tablet (long duration, MR2), single dose, fed
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Maximum Observed Plasma Concentration (Cmax)
Periodo de tiempo: up to 48 h post dose
|
up to 48 h post dose
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Periodo de tiempo: up to 48 h post dose
|
up to 48 h post dose
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]
Periodo de tiempo: up to 48 h post dose
|
up to 48 h post dose
|
Elimination half life
Periodo de tiempo: up to 48 h post dose
|
up to 48 h post dose
|
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Periodo de tiempo: up to 48 h post dose
|
up to 48 h post dose
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de noviembre de 2012
Finalización primaria (Actual)
1 de enero de 2013
Finalización del estudio (Actual)
1 de enero de 2013
Fechas de registro del estudio
Enviado por primera vez
11 de octubre de 2012
Primero enviado que cumplió con los criterios de control de calidad
11 de octubre de 2012
Publicado por primera vez (Estimar)
15 de octubre de 2012
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
24 de enero de 2013
Última actualización enviada que cumplió con los criterios de control de calidad
23 de enero de 2013
Última verificación
1 de enero de 2013
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- B5261003
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre PF-06273340
-
PfizerTerminado
-
University of FloridaTerminadoSíntomas gastrointestinales | Frecuencia de heces | Tiempo de tránsito gastrointestinalEstados Unidos
-
PfizerTerminado
-
PfizerTerminado
-
PfizerTerminado